Your browser doesn't support javascript.
loading
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno, Reno; Mou, Benjamin; Baker, Sarah; Chng, Nick; Arbour, Gregory; Bergman, Alanah; Liu, Mitchell; Schellenberg, Devin; Matthews, Quinn; Huang, Vicky; Mestrovic, Ante; Hyde, Derek; Alexander, Abraham; Carolan, Hannah; Hsu, Fred; Miller, Stacy; Atrchian, Siavash; Chan, Elisa; Ho, Clement; Mohamed, Islam; Lin, Angela; Berrang, Tanya; Bang, Andrew; Jiang, Will; Lund, Chad; Pai, Howard; Valev, Boris; Lefresne, Shilo; Tyldesley, Scott; Olson, Robert A.
Afiliación
  • Eufemon Cereno R; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Kelowna, British Columbia, Canada.
  • Mou B; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Kelowna, British Columbia, Canada.
  • Baker S; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Surrey, British Columbia, Canada.
  • Chng N; British Columbia Cancer, Prince George, British Columbia, Canada.
  • Arbour G; University of British Columbia, British Columbia, Canada.
  • Bergman A; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Liu M; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Schellenberg D; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Surrey, British Columbia, Canada.
  • Matthews Q; British Columbia Cancer, Prince George, British Columbia, Canada.
  • Huang V; British Columbia Cancer, Surrey, British Columbia, Canada.
  • Mestrovic A; British Columbia Cancer, Victoria, British Columbia, Canada.
  • Hyde D; British Columbia Cancer, Kelowna, British Columbia, Canada.
  • Alexander A; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Victoria, British Columbia, Canada.
  • Carolan H; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Hsu F; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Abbotsford, British Columbia, Canada.
  • Miller S; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Prince George, British Columbia, Canada.
  • Atrchian S; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Kelowna, British Columbia, Canada.
  • Chan E; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Ho C; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Surrey, British Columbia, Canada.
  • Mohamed I; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Kelowna, British Columbia, Canada.
  • Lin A; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Kelowna, British Columbia, Canada.
  • Berrang T; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Victoria, British Columbia, Canada.
  • Bang A; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Jiang W; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Prince George, British Columbia, Canada.
  • Lund C; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Surrey, British Columbia, Canada.
  • Pai H; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Victoria, British Columbia, Canada.
  • Valev B; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Victoria, British Columbia, Canada.
  • Lefresne S; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Tyldesley S; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Olson RA; University of British Columbia, British Columbia, Canada; British Columbia Cancer, Prince George, British Columbia, Canada. Electronic address: Rolson2@bccancer.bc.ca.
Radiother Oncol ; 182: 109576, 2023 05.
Article en En | MEDLINE | ID: mdl-36822355
BACKGROUND AND PURPOSE: Stereotactic ablative radiotherapy (SABR) for oligometastases may improve survival, however concerns about safety remain. To mitigate risk of toxicity, target coverage was sacrificed to prioritize organs-at-risk (OARs) during SABR planning in the population-based SABR-5 trial. This study evaluated the effect of this practice on dosimetry, local recurrence (LR), and progression-free survival (PFS). METHODS: This single-arm phase II trial included patients with up to 5 oligometastases between November 2016 and July 2020. Theprotocol-specified planning objective was to cover 95 % of the planning target volume (PTV) with 100 % of the prescribed dose, however PTV coverage was reduced as needed to meet OAR constraints. This trade-off was measured using the coverage compromise index (CCI), computed as minimum dose received by the hottest 99 % of the PTV (D99) divided by the prescription dose. Under-coverage was defined as CCI < 0.90. The potential association between CCI and outcomes was evaluated. RESULTS: 549 lesions from 381 patients were assessed. Mean CCI was 0.88 (95 % confidence interval [CI], 0.86-0.89), and 196 (36 %) lesions were under-covered. The highest mean CCI (0.95; 95 %CI, 0.93-0.97) was in non-spine bone lesions (n = 116), while the lowest mean CCI (0.71; 95 % CI, 0.69-0.73) was in spine lesions (n = 104). On multivariable analysis, under-coverage did not predict for worse LR (HR 0.48, p = 0.37) or PFS (HR 1.24, p = 0.38). Largest lesion diameter, colorectal and 'other' (non-prostate, breast, or lung) primary predicted for worse LR. Largest lesion diameter, synchronous tumor treatment, short disease free interval, state of oligoprogression, initiation or change in systemic treatment, and a high PTV Dmax were significantly associated with PFS. CONCLUSION: PTV under-coverage was not associated with worse LR or PFS in this large, population-based phase II trial. Combined with low toxicity rates, this study supports the practice of prioritizing OAR constraints during oligometastatic SABR planning.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiocirugia / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Radiother Oncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Irlanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Radiocirugia / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Radiother Oncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Irlanda